Biosimilar competition continues to impose challenges, notably impacting legacy products like Neulasta and Enbrel. The sales ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen also purchased oral immunology drug Otezla, which fits well with the Enbrel franchise. Amgen's own large biosimilar portfolio and low manufacturing costs make it a viable biosimilar player ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Investment analysts at William Blair reduced their FY2025 earnings per share estimates for Amgen in a report released on Wednesday, February 5th. William Blair analyst M. Phipps now anticipates that ...

Research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Amgen in a research note issued to ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

notably impacting legacy products like Neulasta and Enbrel. The sales of these drugs have eroded due to competitive pricing from biosimilar counterparts. However, Amgen proactively launched its ...

Sales of cholesterol-lowering medication Repatha rose 45% to $606 million, while sales of arthritis drug Enbrel were flat at $1 billion. In the rare disease space, Amgen's sales of thyroid eye ...